Breakthroughs in treating NSCLC: Targeting KRAS

touchIN CONVERSATION for touchHAEMATOLOGY The presence of anaemia and/or thrombocytopenia complicates the management of patients with myelofibrosis (MF). Listen to expert haematologists consider the burden of cytopenias in patients with MF and discuss strategies to reduce transfusion dependence, improve splenomegaly and personalize treatment with JAK inhibitors. The experts Prof. Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK Dr Laura Fox, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain This touchPODCAST is for HCPs outside of the USA. This activity is supported by an independent medical education grant from GSK. This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP). touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com

touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY Listen to a series of short interviews with three leading experts who provide their insights into early-line management of chronic myeloid leukaemia and the impact on quality of life. The experts: Dr Delphine Rea, Hôpital Saint-Louis, Paris, France  Prof. Andreas Hochhaus, Jena University Hospital, Jena, Germany Prof. Etab Atallah, Medical College of Wisconsin, Milwaukee, WI, USA This activity is for healthcare professionals outside of the USA and UK. This independent medical education is supported by Novartis and is provided by touchIME. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

touchTALKS for touchONCOLOGY Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making. The expert Dr Christine Bestvina, University of Chicago, Chicago, IL, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: www.touchONCOLOGY.com

touchEXPERT FOCUS for touchONCOLOGY Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA.  The experts Prof. Thomas Seufferlein, Ulm University, Ulm, Germany Dr Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust, Oxford, UK Prof. Florian Lordick, University of Leipzig, Leipzig, Germany Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium This touchPODCAST is for HCPs outside of the UK This activity is supported by an independent educational grant from Jazz Pharmaceuticals.  Jointly provided by Partners for Advancing Clinical Education and touchIME.  touchIME is an EBAC® accredited provider.  For further information visit our website:  www.touchONCOLOGY.com

touchPANEL DISCUSSION for touchONCOLOGY and touchENDOCRINOLOGY Listen to a panel of leading experts discuss the optimal management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), with a focus on peptide receptor radionuclide therapy (PRRT). The faculty provide their insights on the current state of the art, the evolving role of PRRT in GEP-NET treatment, and recent data with existing and emerging PRRT agents. The faculty will also consider future developments in this field, including personalized approaches to PRRT, and how they might impact clinical care. The experts: Prof. Thorvardur Halfdanarson, Mayo Clinic Rochester, MN, USA Prof. Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Madrid, Spain Prof. Nicola Fazio, European Institute of Oncology, Milan, Italy This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from ITM Isotope Technologies Munich SE. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchONCOLOGY.com and www.touchENDOCRINOLOGY.com

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/  

touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen to a series of interviews with two medical retina specialists and a biomarker expert who will provide their insights into the pathophysiology of diabetic macular oedema (DMO), including the inflammatory mechanisms of disease and how they may impact treatment. The faculty will also consider the clinical utility of optical coherence tomography (OCT) imaging biomarkers and emerging evidence on the evolving role of corticosteroids in the management of DMO. The experts: Prof. Stela Vujosevic, Medical Retina Unit, IRCCS MultiMedica and University of Milan, Milan, Italy Prof. Francesco Bandello, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy Prof. Laurent Kodjikian, University of Lyon and Croix-Rousse University Hospital, Lyon, France This touchPODCAST is for HCPs outside of the UK and USA. This activity is funded by an independent medical education grant from Alimera Sciences Europe Ltd. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchOPHTHALMOLOGY.com

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of experts in epilepsy as they discuss how to promptly and accurately diagnose and manage Lennox–Gastaut syndrome (LGS). Moderated by a leading European expert, this episode brings together faculty from the Gulf region and Japan, as they explore diagnostic approaches in their regions, before sharing their unique regional perspectives and real-world experience in caring for patients with LGS.   The experts Prof. Nicola Specchio: Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy Dr Raidah Al-Baradie: King Fahad Specialist Hospital, Dammam, Saudi Arabia Dr Taoufik Alsaadi: American Center for Neurology, Abu Dhabi, Dubai, UAE Prof. Eiji Nakagawa: National Center of Neurology and Psychiatry, Tokyo, Japan Prof. Hideo Yamanouchi: Saitama Medical University, Saitama, Japan Chapters The disease state of LGS (00:00–18:47) Managing patients with LGS in the Gulf (18:48–37:00) Managing patients with LGS in Japan (37:01–56:25) This touchPODCAST is for HCPs outside of the UK only.  This activity is supported by an independent medical educational grant from Jazz Pharmaceuticals.  Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit: touchneurologyime.org/diagnosis-treatment-lennox-gastaut-syndrome/

touchEXPERT FOCUS for touchCARDIO Listen to short interviews with two expert cardiologists discussing the role of current and emerging therapeutic classes that aim to address the unmet needs of patients with hypertrophic cardiomyopathy. The faculty will review current therapeutic approaches for managing obstructive versus nonobstructive hypertrophic cardiomyopathy to highlight existing gaps in patient care. They will then discuss the latest data for emerging therapeutic classes and consider how they may address patients’ unmet needs in the future.    The experts Dr Martin Maron, Lahey Hospital & Medical Center, Burlington, MA, USA Dr Michelle Michels, Erasmus MC, Rotterdam, The Netherlands This touchPODCAST is for healthcare professionals outside of the UK. This activity is supported by an independent medical educational grant from Cytokinetics, Inc. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:  https://touchcardio.com/

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   touchONCOLOGY: https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ touchRESPIRATORY: https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/